Home Featured Page 289

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for...

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a...

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.]...

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes...

The Pitfalls and Challenges of Psychedelic Medicine

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and...

Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT

Numinus to expand state-of-the-art psychedelics research laboratory

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.